Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
RéversibilitéGestion des complications
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les anomalies des motifs EF Hands ?
Les facteurs incluent des prédispositions génétiques et des expositions environnementales.
Facteurs de risquePrédispositions génétiques
#2
L'âge influence-t-il les motifs EF Hands ?
Oui, le vieillissement peut affecter la fonction des motifs EF Hands et la signalisation calcique.
ÂgeVieillissement
#3
Le mode de vie joue-t-il un rôle dans les risques ?
Un mode de vie sédentaire et une mauvaise alimentation augmentent les risques.
Mode de vieAlimentation
#4
Les antécédents familiaux sont-ils un facteur de risque ?
Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque.
Antécédents familiauxMaladies génétiques
#5
Les infections peuvent-elles affecter les motifs EF Hands ?
Certaines infections peuvent perturber la signalisation calcique, affectant ces motifs.
InfectionsSignalisation calcique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Motifs EF Hands : Questions médicales les plus fréquentes",
"headline": "Motifs EF Hands : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Motifs EF Hands : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Motifs EF Hands"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Motifs à hélice-boucle-hélice",
"url": "https://questionsmedicales.fr/mesh/D018257",
"about": {
"@type": "MedicalCondition",
"name": "Motifs à hélice-boucle-hélice",
"code": {
"@type": "MedicalCode",
"code": "D018257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.500.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Motifs EF Hands",
"alternateName": "EF Hand Motifs",
"code": {
"@type": "MedicalCode",
"code": "D020832",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Peter B Stathopulos",
"url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Qi-Tong Lin",
"url": "https://questionsmedicales.fr/author/Qi-Tong%20Lin",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Biraj B Kayastha",
"url": "https://questionsmedicales.fr/author/Biraj%20B%20Kayastha",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, 74078, USA."
}
},
{
"@type": "Person",
"name": "Aya Kubo",
"url": "https://questionsmedicales.fr/author/Aya%20Kubo",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, 74078, USA."
}
},
{
"@type": "Person",
"name": "Jacob Burch-Konda",
"url": "https://questionsmedicales.fr/author/Jacob%20Burch-Konda",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, 74078, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.",
"datePublished": "2023-01-18",
"url": "https://questionsmedicales.fr/article/36652189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13187-023-02264-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate-Specific Antigen Screening in Transgender Patients.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36344317",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eururo.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35860909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pros.24414"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37702749",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00120-023-02189-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes chimiques",
"item": "https://questionsmedicales.fr/mesh/D055598"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes biochimiques",
"item": "https://questionsmedicales.fr/mesh/D001669"
},
{
"@type": "ListItem",
"position": 4,
"name": "Conformation moléculaire",
"item": "https://questionsmedicales.fr/mesh/D008968"
},
{
"@type": "ListItem",
"position": 5,
"name": "Conformation des protéines",
"item": "https://questionsmedicales.fr/mesh/D011487"
},
{
"@type": "ListItem",
"position": 6,
"name": "Éléments structuraux des protéines",
"item": "https://questionsmedicales.fr/mesh/D000072416"
},
{
"@type": "ListItem",
"position": 7,
"name": "Motifs à hélice-boucle-hélice",
"item": "https://questionsmedicales.fr/mesh/D018257"
},
{
"@type": "ListItem",
"position": 8,
"name": "Motifs EF Hands",
"item": "https://questionsmedicales.fr/mesh/D020832"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Motifs EF Hands - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Motifs EF Hands",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Motifs EF Hands",
"description": "Comment diagnostiquer un motif EF Hand ?\nQuels tests sont utilisés pour les motifs EF Hands ?\nLes motifs EF Hands sont-ils visibles par imagerie ?\nPeut-on identifier des mutations dans les motifs EF Hands ?\nQuel rôle joue la bioinformatique dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Motifs EF Hands",
"description": "Quels symptômes sont associés aux motifs EF Hands ?\nLes motifs EF Hands sont-ils liés à des maladies ?\nComment les motifs EF Hands affectent-ils la signalisation cellulaire ?\nY a-t-il des signes cliniques de dysfonction des motifs EF Hands ?\nLes motifs EF Hands influencent-ils le métabolisme ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Motifs EF Hands",
"description": "Peut-on prévenir les anomalies des motifs EF Hands ?\nY a-t-il des facteurs environnementaux à considérer ?\nComment le stress influence-t-il les motifs EF Hands ?\nL'exercice physique a-t-il un impact sur ces motifs ?\nLes suppléments de calcium sont-ils bénéfiques ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Motifs EF Hands",
"description": "Quels traitements ciblent les motifs EF Hands ?\nPeut-on modifier les motifs EF Hands par thérapie génique ?\nLes médicaments peuvent-ils influencer les motifs EF Hands ?\nY a-t-il des approches expérimentales pour traiter les anomalies ?\nComment la nutrition peut-elle influencer les motifs EF Hands ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Motifs EF Hands",
"description": "Quelles complications peuvent survenir avec des motifs EF Hands défectueux ?\nLes motifs EF Hands sont-ils liés à des cancers ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de maladies cardiovasculaires ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Motifs EF Hands",
"description": "Quels sont les facteurs de risque pour les anomalies des motifs EF Hands ?\nL'âge influence-t-il les motifs EF Hands ?\nLe mode de vie joue-t-il un rôle dans les risques ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLes infections peuvent-elles affecter les motifs EF Hands ?",
"url": "https://questionsmedicales.fr/mesh/D020832?mesh_terms=Prostate-Specific+Antigen#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un motif EF Hand ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses biochimiques et des études de structure protéique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les motifs EF Hands ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la spectroscopie RMN et la cristallographie aux rayons X sont utilisées."
}
},
{
"@type": "Question",
"name": "Les motifs EF Hands sont-ils visibles par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils nécessitent des méthodes biochimiques pour être étudiés, pas d'imagerie classique."
}
},
{
"@type": "Question",
"name": "Peut-on identifier des mutations dans les motifs EF Hands ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques de séquençage génétique peuvent révéler des mutations affectant ces motifs."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la bioinformatique dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bioinformatique aide à prédire la structure et la fonction des motifs EF Hands."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux motifs EF Hands ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les motifs EF Hands ne présentent pas de symptômes directs, mais affectent des fonctions cellulaires."
}
},
{
"@type": "Question",
"name": "Les motifs EF Hands sont-ils liés à des maladies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans ces motifs peuvent être associées à des maladies comme l'ataxie."
}
},
{
"@type": "Question",
"name": "Comment les motifs EF Hands affectent-ils la signalisation cellulaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils régulent la signalisation calcique, influençant divers processus cellulaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques de dysfonction des motifs EF Hands ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes indirects peuvent apparaître, comme des troubles neurologiques ou musculaires."
}
},
{
"@type": "Question",
"name": "Les motifs EF Hands influencent-ils le métabolisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle dans le métabolisme cellulaire en régulant le calcium."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des motifs EF Hands ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines peut affecter la fonction des motifs EF Hands."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il les motifs EF Hands ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut perturber la signalisation calcique, affectant indirectement ces motifs."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur ces motifs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice régule la signalisation calcique, ce qui peut soutenir la fonction des motifs."
}
},
{
"@type": "Question",
"name": "Les suppléments de calcium sont-ils bénéfiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments peuvent aider à maintenir un bon équilibre calcique, soutenant la fonction."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les motifs EF Hands ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques pour les motifs EF Hands."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les motifs EF Hands par thérapie génique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait potentiellement corriger des mutations affectant ces motifs."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils influencer les motifs EF Hands ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments modulent la signalisation calcique, indirectement affectant ces motifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches expérimentales pour traiter les anomalies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des peptides et des inhibiteurs ciblant les motifs EF Hands."
}
},
{
"@type": "Question",
"name": "Comment la nutrition peut-elle influencer les motifs EF Hands ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adéquate en calcium et en magnésium peut soutenir leur fonction."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des motifs EF Hands défectueux ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des troubles neurologiques et musculaires."
}
},
{
"@type": "Question",
"name": "Les motifs EF Hands sont-ils liés à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien potentiel entre des anomalies et certains types de cancer."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des limitations fonctionnelles et des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies cardiovasculaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements calciques peuvent contribuer à des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des motifs EF Hands ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les motifs EF Hands ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la fonction des motifs EF Hands et la signalisation calcique."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle dans les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter les motifs EF Hands ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent perturber la signalisation calcique, affectant ces motifs."
}
}
]
}
]
}
RG Neuroplasticity, Leibniz Institute for Neurobiology, Magdeburg, Germany.
Leibniz Group 'Dendritic Organelles and Synaptic Function', University Medical Center Hamburg-Eppendorf, Center for Molecular Neurobiology, ZMNH, Hamburg, Germany.
Institute for Biological Instrumentation of the Russian Academy of Sciences, Federal Research Center Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences, 142290 Pushchino, Russia. epermyak@yandex.ru.
Department of Biomedical Engineering, Pushchino State Institute of Natural Sciences, 142290 Pushchino, Russia. epermyak@yandex.ru.
There is controversy on prostate cancer screening with the prostate-specific antigen (PSA) test in the USA, and as a result, there has been an increased push for physicians to have a thorough discussi...
Approximately 0.4-1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender. Among transgender women (TW), t...
To assess our current understanding of CaP incidence and prostate-specific antigen (PSA) screening in TW....
We performed a nonsystematic narrative review of all PubMed publications through June 2022 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Given ...
There is no consensus regarding PSA screening in TW from any of the major societies, and TW are largely absent from guidelines. Case report data suggest that TW with CaP may have more aggressive disea...
We are in the infancy of our understanding of PSA screening in TW. Important avenues for future research include understanding the risks/benefits of PSA screening in TW, how best to mitigate potential...
We examined patterns of prostate cancer screening for transgender women. Little is known about prostate cancer incidence or screening in this population. Additional research is needed to establish gui...
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant prostate cancer ...
In this bicentric analysis, we included 184 mCRPC patients treated with...
A total of 114/184 patients (62.0%) showed any PSA decline (PSA response >50%, 55/184 [29.9%]). For individuals exhibiting a PSA decline >50%, OS of 19 months was significantly longer relative to nonr...
In mCRPC patients scheduled for RLT, early biochemical response was tightly linked to prolonged survival, irrespective of the magnitude of PSA decline. As such, even in patients with PSA decrease of l...
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Prostate-specific antigen (PSA) screening for prostate cancer is controversial but may be associated with benefit for certain high-risk groups....
To evaluate associations of county-level PSA screening prevalence with prostate cancer outcomes, as well as variation by sociodemographic and clinical factors....
This cohort study used data from cancer registries based in 8 US states on Hispanic, non-Hispanic Black, and non-Hispanic White men aged 40 to 99 years who received a diagnosis of prostate cancer betw...
County-level PSA screening prevalence was estimated using the Behavior Risk Factor Surveillance System survey data from 2004, 2006, 2008, 2010, and 2012 and weighted by population characteristics....
Multivariable logistic, Cox proportional hazards regression, and competing risks models were fit to estimate adjusted odds ratios (AOR) and adjusted hazard ratios (AHR) for associations of county-leve...
Of 814 987 men with prostate cancer, the mean (SD) age was 67.3 (9.8) years, 7.8% were Hispanic, 12.2% were non-Hispanic Black, and 80.0% were non-Hispanic White; 17.0% had advanced disease. There wer...
This population-based cohort study of men with prostate cancer suggests that higher county-level prevalence of PSA screening was associated with lower odds of advanced disease, all-cause mortality, an...
The incidence rate of prostate cancer (PCa) has continued to rise in Korea. This study aimed to construct and evaluate a 5-year PCa risk prediction model using a cohort with PSA < 10 ng/mL by incorpor...
The PCa risk prediction model including PSA levels and individual risk factors was constructed using a cohort of 69,319 participants from the Kangbuk Samsung Health Study. 201 registered PCa incidence...
The risk prediction model included age, smoking status, alcohol consumption, family history of PCa, past medical history of dyslipidemia, cholesterol levels, and PSA level. Especially, an elevated PSA...
Our risk prediction model was effective in predicting PCa in a population according to PSA levels. When PSA levels are inconclusive, an assessment of both PSA and specific individual risk factors (e.g...
For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ...
Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe...
The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos...
PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...
To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa)....
The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an...
tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ...
With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
